Jessica Fye
Stock Analyst at JP Morgan
(4.17)
# 444
Out of 4,944 analysts
195
Total ratings
59.84%
Success rate
10.16%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Neutral | $60 → $63 | $64.04 | -1.62% | 14 | Aug 7, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $348 → $475 | $429.93 | +10.48% | 8 | Aug 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $245 → $254 | $196.02 | +29.58% | 13 | Jul 29, 2025 | |
| ONC BeOne Medicines | Maintains: Overweight | $321 → $345 | $288.10 | +19.75% | 3 | Jul 17, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $515 → $517 | $387.77 | +33.33% | 9 | Jul 14, 2025 | |
| INCY Incyte | Maintains: Neutral | $68 → $67 | $81.61 | -17.90% | 7 | Jul 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $108 → $113 | $56.86 | +98.73% | 4 | Jul 14, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $350 → $330 | $301.39 | +9.49% | 17 | Jul 8, 2025 | |
| INSM Insmed | Maintains: Overweight | $90 → $111 | $122.00 | -9.02% | 8 | Jul 8, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $48 | $41.41 | +15.91% | 5 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $25.66 | +1.33% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $116 | $111.00 | +4.50% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.35 | +55.69% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $31.87 | +56.89% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $11.34 | +146.91% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $113.33 | +84.42% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $13.22 | +81.54% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $27.43 | -5.21% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $12.53 | +139.43% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $28.48 | +89.61% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $64.72 | -39.74% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $13.53 | -3.92% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $23.60 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.91 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.79 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.88 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $36.99 | +105.46% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.70 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.53 | +1,337.91% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.06 | +560.38% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.07 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.48 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.85 | - | 1 | Feb 8, 2018 |
Halozyme Therapeutics
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $64.04
Upside: -1.62%
Alnylam Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $348 → $475
Current: $429.93
Upside: +10.48%
Ascendis Pharma
Jul 29, 2025
Maintains: Overweight
Price Target: $245 → $254
Current: $196.02
Upside: +29.58%
BeOne Medicines
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $288.10
Upside: +19.75%
Vertex Pharmaceuticals
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $387.77
Upside: +33.33%
Incyte
Jul 14, 2025
Maintains: Neutral
Price Target: $68 → $67
Current: $81.61
Upside: -17.90%
BioMarin Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $56.86
Upside: +98.73%
United Therapeutics
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $301.39
Upside: +9.49%
Insmed
Jul 8, 2025
Maintains: Overweight
Price Target: $90 → $111
Current: $122.00
Upside: -9.02%
Ionis Pharmaceuticals
Jun 12, 2025
Maintains: Neutral
Price Target: $45 → $48
Current: $41.41
Upside: +15.91%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $25.66
Upside: +1.33%
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $111.00
Upside: +4.50%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.35
Upside: +55.69%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $31.87
Upside: +56.89%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $11.34
Upside: +146.91%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $113.33
Upside: +84.42%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $13.22
Upside: +81.54%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $27.43
Upside: -5.21%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $12.53
Upside: +139.43%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $28.48
Upside: +89.61%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $64.72
Upside: -39.74%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $13.53
Upside: -3.92%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $23.60
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.91
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.79
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.88
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $36.99
Upside: +105.46%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.70
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.53
Upside: +1,337.91%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.06
Upside: +560.38%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.07
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.48
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $6.85
Upside: -